Published 2021-09-01
“…Ying Wang,1 Xiaoxiao Zhao,1 Peng Zhou,1 Chen Liu,1 Zhaoxue Sheng,1,2 Jiannan Li,1 Jinying Zhou,1 Runzhen Chen,1 Yi Chen,1 Li Song,1 Hanjun Zhao1 *, Hongbing Yan3 𪇞partment of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases,
Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, People’s Republic of China; 2Department of Cardiology, China-Japan Friendship Hospital, Beijing, People’s Republic of China; 3Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, People’s Republic of China* These authors contributed equally to this workCorrespondence: Hongbing YanDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, No. 12, Langshan Road, Xili Street, Nanshan District, Shenzhen, 518000, People’s Republic of ChinaTel +86-10-88322285Email hbyanfuwai2018@163.comHanjun ZhaoDepartment of Cardiology, Fuwai Hospital, Chinese Academy of Medical Sciences, No. 167 Beilishi Road, Xicheng District, Beijing, 100037, People’s Republic of ChinaTel +86-15210020808Email 15210020808@163.comBackground: Culprit‑plaque morphology [plaque rupture (PR) and plaque erosion (PE) identified by optical coherence tomography (OCT)] and biomarker of vascular inflammation, pentraxin-3 (PTX3), have been reported to influence clinical outcomes in coronary diseases. …”
Get full text
Article